Senores Pharmaceuticals , an Indian pharmaceutical company, has made a significant move to expand its presence in the United States market. The company has established a new step-down subsidiary in the U.S. and acquired a majority stake in a Delaware-based pharmaceutical firm, marking a strategic step towards international growth.

Key Developments

1. U.S. Subsidiary Formation: Senores Pharmaceuticals has formed a wholly-owned subsidiary in the United States, named Senores Pharmaceuticals, Inc. (SPI).

2. Strategic Acquisition: SPI has entered into a Limited Liability Company Agreement (LLCA) dated November 04, 2025, acquiring a 51% membership interest in Zoraya Pharmaceuticals, LLC, a company based in Delaware, USA.

3. New Step-Down Subsidiary: As a result of this acquisition, Zoraya Pharmaceuticals, LLC has become a step-down subsidiary of Senores Pharmaceuticals Limited.

Details of the Acquisition

Strategic Implications

This move represents a significant step for Senores Pharmaceuticals in its international expansion strategy. By establishing a direct presence in the U.S. and acquiring a majority stake in a local company, Senores aims to strengthen its foothold in the world's largest pharmaceutical market.

The formation of the U.S. subsidiary and the subsequent acquisition may provide Senores with several potential benefits:

1. Direct access to the U.S. pharmaceutical market
2. Potential for technology and knowledge transfer
3. Expanded manufacturing and distribution capabilities
4. Enhanced ability to navigate U.S. regulatory landscape

Additional Company Update

In a separate development, Senores Pharmaceuticals also reported that its material subsidiary, Havix Group Inc. D/B/A Aavis Pharmaceuticals, has successfully addressed and resolved minor observations from a recent USFDA inspection. The U.S. Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) on November 04, 2025, following the inspection of Havix's manufacturing facility in Hoschton, Georgia, which took place from July 21 to July 25, 2025.

This positive outcome from the USFDA inspection further strengthens Senores Pharmaceuticals' position in the U.S. market and underscores the company's commitment to maintaining high quality standards in its operations.

As Senores Pharmaceuticals continues to expand its global footprint, investors and industry observers will be watching closely to see how these strategic moves impact the company's growth and performance in the competitive pharmaceutical sector.

Senores Pharmaceuticals Limited, a prominent player in the pharmaceutical industry, has announced a significant investment of $2 million (approximately ₹16.6 crore) in its wholly owned US subsidiary, Senores Pharmaceuticals Inc. (SPI). This strategic move aligns with the company's commitment to strengthening its presence in the American market and supporting its overseas operations.

Investment Details

The investment, made through a rights issue, involves the acquisition of 120,480 equity shares at $16.60 per share, totaling $1,999,968. This capital injection is part of Senores Pharmaceuticals' planned utilization of its Initial Public Offer (IPO) proceeds, as outlined in the company's prospectus dated December 24, 2024.

About Senores Pharmaceuticals Inc.

Senores Pharmaceuticals Inc., incorporated on January 28, 2021, plays a crucial role in the parent company's US operations. SPI is responsible for:

• Holding intellectual properties used by Senores Pharmaceuticals
• Managing ANDA (Abbreviated New Drug Application) approvals
• Entering into agreements with marketing partners in the United States

Financial Performance

The US subsidiary has shown impressive growth over the past three years:

This consistent growth underscores the strategic importance of SPI to Senores Pharmaceuticals' global operations.

Regulatory Compliance

The company has confirmed that the investment complies with all necessary regulations, including:

• Approval under the Foreign Exchange Management Act, 1999
• Adherence to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Strategic Implications

This investment represents a significant step for Senores Pharmaceuticals in reinforcing its US market presence. By allocating capital to its American subsidiary, the company aims to:

1. Enhance working capital for US operations
2. Support the growth and expansion of its intellectual property portfolio
3. Strengthen relationships with marketing partners in the United States

The move is expected to contribute to Senores Pharmaceuticals' overall global strategy and potentially drive future growth in the competitive pharmaceutical market.

As the pharmaceutical landscape continues to evolve, Senores Pharmaceuticals' investment in its US subsidiary demonstrates its commitment to maintaining a strong foothold in one of the world's largest pharmaceutical markets.